Affyimmune Competitors and Similar CompaniesClear all

Affyimmune's competitors and similar companies include Legend Biotech, Seagen, Ikena Oncology and Gliknik.

	Affyimmune AffyImmune Therapeutics is a biotechnology company that focuses on cell-based immunotherapies for cancer.	Legend Biotech Legend Biotech is a biopharmaceutical company engaged in the discovery and development of cell therapies for oncology and other indications.	Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer.	Ikena Oncology Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment.	Gliknik Gliknik is a biopharmaceutical company creating therapies for people living with cancer and immune disorders.
Founding Date	Founding Date 2016	Founding Date 2014	Founding Date 1998	Founding Date 2016	Founding Date 2007
Type	Type Private	Type Public	Type Subsidiary	Type Public	Type Private
Tags	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy
Locations	Locations Natick, US HQ Newton, US	Locations Somerset, US HQ Ghent, BE Nanjing, CN Hong Kong, HK Dublin, IE Piscataway, US	Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more	Locations Boston, US HQ	Locations Baltimore, US HQ
Employees	Employees 4	Employees 2,90012% increase	Employees 3,25622% increase	Employees 5052% increase	Employees 9
Valuation ($)	Valuation ($) N/A	Valuation ($) 8.4 b	Valuation ($) N/A	Valuation ($) 82.5 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $1b (FY, 2025)	Revenue (est.) $2b (FY, 2022)	Revenue (est.) $800k (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $408.1m (FY, 2025)	Cost of goods $410.1m (FY, 2022)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $620.8m (FY, 2025)	Gross profit $1.6b (FY, 2022)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income ($296.8m) (FY, 2025)	Net income ($610.3m) (FY, 2022)	Net income ($45.3m) (FY, 2025)	Net income N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 150.5m	Total funding raised $ 164m	Total funding raised $ 49m	Total funding raised $ 65.1m